Ocugen, Inc. (OCGN) is a biopharmaceutical company based in the United States with a focus on discovering, developing, and commercializing transformative therapies for rare diseases and blindness. Established in 2013, the company's primary mission is to address the unmet medical needs of patients with debilitating eye diseases that significantly impact their quality of life.
Ocugen's groundbreaking research and innovative gene therapy platform are at the heart of the company's ambition. Their research pipeline includes potential treatments for diseases like age-related macular degeneration and diabetic macular edema. The company is making significant strides in applying novel biological insights to produce new solutions that could change patients' lives forever.
One of Ocugen's most promising projects is COVAXIN, a coronavirus vaccine that received emergency use authorization in India. COVAXIN is a whole-virion inactivated COVID-19 vaccine manufactured by Bharat Biotech in partnership with the Indian Council of Medical Research – National Institute of Virology (ICMR-NIV). Ocugen is collaborating with Bharat Biotech to introduce COVAXIN to the U.S. market.
Ocugen's pioneering approach, along with their journey to provide innovative life-changing treatments, has earned the company recognition within the biopharmaceutical industry and beyond. Furthermore, through strong collaborations and partnerships, Ocugen is able to access state-of-the-art technology and world-class expertise, which bolsters its ability to meet its ambitious vision of helping patients with unmet medical needs.
Despite the extensive challenges of drug development, Ocugen continually strives to deliver radically improved treatments to patients who currently have few or no options. It's this dedicated commitment to making a difference that positions Ocugen as a leader in the realm of biopharmaceutical innovation.
The company is listed on the NASDAQ under the symbol "OCGN" and continues to make waves in the medical research community. Despite the inherent risks and uncertainties associated with pharmaceutical research, Ocugen remains steadfast in its pursuit, leveraging cutting-edge science and technology, to enhance and expand its product portfolio, thereby paving the way toward a promising future for those affected by serious diseases and blindness. It is a company truly driven by its mission to improve capability and continuity of care.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Ocugen Inc. has received provisional approval for its gene therapy candidate OCU400 in the Bahamas. This development is for the treatment of retinitis pigmentosa, a significant step for the company's modifier gene therapy platform.
Ocugen (OCGN) received provisional approval and priority designation in the Bahamas for its experimental gene therapy, OCU400, aimed at treating retinitis pigmentosa. This marks a significant step in the company's global expansion efforts, with plans to treat the first patient in the Bahamas within 90 days. Ocugen also has other late-stage eye-disease programs and is pursuing commercialization opportunities in various international markets.
Ocugen (NASDAQ:OCGN) has received provisional approval and priority designation in The Bahamas for OCU400, an investigational gene therapy for retinitis pigmentosa. The company plans to offer OCU400 through an expanded access program and aims to treat the first patient within 90 days of full approval. Ocugen anticipates topline Phase 3 data in Q1 2027 and a Biologics License Application submission in Q2 2027.
Ocugen (NASDAQ: OCGN) has successfully raised $40 million through a registered direct offering, selling 20 million shares of common stock at $2.00 each to a single institutional healthcare-focused investor. The biotech company plans to use these proceeds to fund its three late-stage gene therapy programs targeting blindness diseases, with the goal of submitting biologics license applications by 2028. This financing strengthens Ocugen's balance sheet for its capital-intensive clinical trials.
Ocugen, a Malvern, Pennsylvania-based biopharmaceutical company, announced it has dosed the first patient in its global Phase 3 registrational trial for OCU410, a modifier gene therapy for geographic atrophy. This milestone follows the FDA granting OCU410 Regenerative Medicine Advanced Therapy designation. The therapy aims to address the unmet need for effective treatments for geographic atrophy, a leading cause of irreversible central vision loss, by modulating multiple biological pathways.